Katrine Aagaard Myhr

Katrine Aagaard Myhr

Auto-generated profile, based on publicly available information

Katrine Aagaard Myhr

Department of Cardiology, The Heart Centre, Copenhagen University Hospital – Rigshospitalet, Copenhagen, Denmark

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2023 in The International Journal of Cardiovascular Imaging
Verified
Journal Article
Open access
PDF file
KMKatrine A. Myhr
Katrine A. Myhr
AZAmanda H. Zinglersen
Amanda H. Zinglersen
RPRedi Pecini
Redi Pecini
SJSvein Ketil Jacobsen
Svein Ketil Jacobsen
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that carries increased risk of cardiovascular disease; however, the underlying pathophysiological mechanisms remain poorly understood. We aimed to investigate the prevalence and degree of myocardial fibrosis in SLE patients and associated disease characteristics. Forty-nine SLE patients (89% female, mean age 52 ± 13 years, median disease duration 19 (11–25) years) and 79 sex-and age-matched healthy controls were included. CMR with T1 mapping was performed on SLE patients and healthy controls. Fifty-one SLE patients received gadolinium contrast for the evaluation of late gadolinium enhancement (LGE) and extra cellular volume (ECV). Multiple linear regression analyses were performed to investigate the association between markers of myocardial fibrosis on CMR (LGE, T1, ECV) and SLE-related variables [clinical disease activity, lupus nephritis, chronic kidney disease, anti-cardiolipin and/or anti-beta-2 glycoprotein I antibodies, and lupus anticoagulant (LAC)] with adjustment for traditional risk factors. T1 values were elevated in SLE patients compared to healthy controls (1031 ± 36 ms vs. 1019 ± 25 ms, p = 0.01). LGE was present in 20% of SLE patients who received gadolinium contrast. On multivariable analysis, LAC was associated with LGE in SLE patients (β = 3.87, p = 0.02). Neither T1 nor ECV associated with SLE disease characteristics; however, there was a trend towards an association between LAC and T1 (β = 16.9, p = 0.08). SLE patients displayed signs of myocardial fibrosis on CMR that were associated with the presence of LAC. These findings support the pathophysiological understanding of LAC as a mediator of microvascular and subsequent myocardial dysfunction. Graphical abstract

12 March 2024 in European Heart Journal - Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
KMKatrine Aagaard Myhr
Katrine Aagaard Myhr
LALiv Andrés-Jensen
Liv Andrés-Jensen
BLBjørn Strøier Larsen
Bjørn Strøier Larsen
JKJoakim Bo Kunkel
Joakim Bo Kunkel
CKCharlotte Kristensen
Charlotte Kristensen
RPRedi Pecini
Redi Pecini
Aims: Cardiovascular diseases manifest differently in males and females, potentially influenced by inherent sex- and age-related differences in myocardial tissue composition. Such inherent differences are not well-established in the literature. With this study using cardiac magnetic resonance (CMR) native T1 mapping, we aim to determine the effect of sex and age on myocardial tissue composition in healthy individuals. Methods and results: CMR native T1 mapping was performed in 276 healthy individuals (55% male, age 8­­–84 years) on a 1.5 Tesla scanner using a MOLLI 5(3)3 acquisition scheme. Additionally, 30 healthy participants (47% male, age 24–68 years) underwent a 1-year follow-up CMR to assess the longitudinal changes of native T1. Mean native T1 values were 1000 ± 22 ms in males and 1022 ± 23 ms in females [mean difference (MD) = 22 ms, 95% confidence interval (CI) (17, 27)]. Female sex was associated with higher native T1 in multivariable linear regression adjusting for age, heart rate, left ventricular mass index, and blood T1 [β=10 ms, 95% CI (3.4, 15.8)]. There was no significant interaction between sex and age (P = 0.27). Further, age was not associated with native T1 [β=0.1 ms, 95% CI (−0.02, 0.2)], and native T1 did not change during a 1-year period [MD −4 ms, 95% CI (−11, 3)]. Conclusion: Female sex was associated with higher native T1; however, there was no association between age and native T1. Additionally, there was no evidence of an interaction between sex and age. Our findings indicate intrinsic sex-based disparities in myocardial tissue composition.

2 August 2018 in Echocardiography
Verified
Journal Article
Closed access
PDF file
KMKatrine A. Myhr Mb
Katrine A. Myhr Mb
FPFrederik H. G. Pedersen
Frederik H. G. Pedersen
CKCharlotte B. Kristensen
Charlotte B. Kristensen
LVLasse Visby
Lasse Visby
CHChristian Hassager
Christian Hassager
RMRasmus Mogelvang
Rasmus Mogelvang

13 January 2025 in Rheumatology International
Verified
Journal Article
Open access
PDF file
LZLise Zinglersen
Lise Zinglersen
AZAmanda Hempel Zinglersen
Amanda Hempel Zinglersen
KMKatrine Aagaard Myhr
Katrine Aagaard Myhr
MHMarie-Louise Hermansen
Marie-Louise Hermansen
KKKlaus Fuglsang Kofoed
Klaus Fuglsang Kofoed
SJSvein Ketil Jacobsen
Svein Ketil Jacobsen
To investigate if progression of coronary artery calcification (CAC) in patients with systemic lupus erythematosus (SLE) is associated with renal and traditional cardiovascular risk factors as well as incidence of myocardial infarctions. CAC progression was evaluated by cardiac computed tomography (CT) at baseline and after 5 years. Multivariable Poisson regression was applied to investigate associations between CAC progression and baseline values for traditional cardiovascular risk factors, CAC, SLE disease duration, lupus nephritis, and renal function. Regarding renal function, three groups were defined based on eGFR. Further, we analysed association between CAC progression and myocardial infarction during follow-up. Of the 147 SLE patients, 99 had cardiac CT at baseline and 5-year follow-up, with a total of 502 patient-years. At baseline, their median age was 47 years, median SLE disease duration was 14 years, 88% were women, 58% had lupus nephritis, and the median eGFR was 99 mL/min/1.73m2. 38/99 (39%) had CAC progression. CAC progression was associated with smoking (ever) (relative risk [RR] 1.69, CI95% 1.19–2.40), SLE disease duration (RR per year 1.03, CI95% 1.01–1.04), and CAC presence (RR 2.52, CI95% 1.68–3.78) at baseline. During follow-up, myocardial infarction occurred in three (7.9%) CAC progressors and in two (3.3%) patients who did not have CAC at any time (RR 2.1, CI95% 0.0-5.5). In this study, progression of CAC was associated with smoking, SLE disease duration and the prior presence of CAC, but it was inconclusive as to associations with renal involvement and incidence of MI.

20 September 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
AZAmanda Hempel Zinglersen
Amanda Hempel Zinglersen
IDIda Lynghøj Drange
Ida Lynghøj Drange
KMKatrine Aagaard Myhr
Katrine Aagaard Myhr
AFAndreas Fuchs
Andreas Fuchs
MPMogens Pfeiffer-Jensen
Mogens Pfeiffer-Jensen
SJSvein Ketil Jacobsen
Svein Ketil Jacobsen
Introduction Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. SLE is treated with immunosuppressants with suboptimal efficacy and high risk of serious side effects. Patients with SLE have increased risk of mortality, organ damage and debilitating treatment-resistant fatigue. Autonomic nervous system dysfunction (AD) is present in approximately half of the patients and may promote autoimmunity by weakening the vagally mediated anti-inflammatory reflex. Recent studies suggest that transcutaneous vagus nerve stimulation (tVNS) has few side effects and beneficial effects on fatigue, pain, disease activity and organ function. This study investigates whether adjuvant tVNS improves measures of fatigue (primary end point), AD, clinical disease activity, inflammation, pain, organ function and quality of life. Hence, this study will contribute to the understanding of AD as a potentially important precursor of fatigue, disease activity, progression and complications in SLE, and how tVNS mechanistically may attenuate this. As adjuvant tVNS use may reduce the need for traditional immunosuppressive therapy, this trial may prompt a shift in the treatment of SLE and potentially other autoimmune disorders. Methods and analysis Eighty-four patients with SLE with fatigue and AD will be randomised 1:1 to active or sham tVNS in this double-blinded parallel-group study. In period 1 (1 week), participants will receive a 4 min tVNS 4 times daily and report on fatigue daily. After a 2-week pause, period 2 (8 weeks) will entail tVNS twice daily and participants will report on fatigue, pain and disease activity weekly. Secondary end points will be assessed before and after each period and after 1 week in period 2. Ethics and dissemination The study is approved by the Danish Medical Research Ethical Committees (case no: 2120231) and results will be published in international peer-reviewed journals. Trial registration number NCT05315739.

10 September 2020 in The International Journal of Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
KMK. A. Myhr
K. A. Myhr
CKC. B. Kristensen
C. B. Kristensen
FPF. H. G. Pedersen
F. H. G. Pedersen
CHC. Hassager
C. Hassager
NVN. Vejlstrup
N. Vejlstrup
RMR. Mogelvang
R. Mogelvang